These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3481 related items for PubMed ID: 11957750

  • 1. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM, García Rodríguez J, Escaf Barmadah S, Raigoso P, Rodríguez Martínez JJ, Allende MT, Casasola Chamorro J, Rodríguez Faba O, Martín Benito JL, Regadera Sejas FJ.
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [Abstract] [Full Text] [Related]

  • 2. [The BTA stat test in the follow-up for bladder cancer].
    Gutiérrez Baños JL, Martín García B, de Diego Rodríguez E, Hernández Rodríguez R, Portillo Martín JA, Correas Gómez MA, del Valle Schaan JI, Roca Edreira A, Rado Velázquez MA.
    Arch Esp Urol; 1999 Oct; 52(8):856-61. PubMed ID: 10589117
    [Abstract] [Full Text] [Related]

  • 3. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J, Rodríguez-Martínez JJ, Barmadah SE, García Rodríguez J, Allende DM, Jalon A, Gonzalez R, Alvarez-Múgica M.
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [Abstract] [Full Text] [Related]

  • 4. [Quantification of bladder tumor antigen (BTA trak) and its correlation with bladder cancer grade and stage].
    Rodríguez Martínez JJ, Escaf Barmadah S, Allende MT, Raigoso P, Martín Benito JL, Pérez García FJ, Fernández Gómez JM.
    Arch Esp Urol; 2000 May; 53(1):1-6. PubMed ID: 10730418
    [Abstract] [Full Text] [Related]

  • 5. BTA TRAK urine test increases the efficacy of cytology in the diagnosis of low-grade transitional cell carcinoma of the bladder.
    Gibanel R, Ribal MJ, Filella X, Ballesta AM, Molina R, Alcaraz A, Alcover JB.
    Anticancer Res; 2002 May; 22(2B):1157-60. PubMed ID: 12168917
    [Abstract] [Full Text] [Related]

  • 6. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
    Raitanen MP, Leppilahti M, Tuhkanen K, Forssel T, Nylund P, Tammela T, FinnBladder Group.
    Ann Chir Gynaecol; 2001 May; 90(4):261-5. PubMed ID: 11820414
    [Abstract] [Full Text] [Related]

  • 7. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma.
    Babjuk M, Soukup V, Pesl M, Kostírová M, Drncová E, Smolová H, Szakacsová M, Getzenberg R, Pavlík I, Dvorácek J.
    Urology; 2008 Apr; 71(4):718-22. PubMed ID: 18387400
    [Abstract] [Full Text] [Related]

  • 8. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment.
    Bartoletti R, Dal Canto M, Cai T, Piazzini M, Travaglini F, Gavazzi A, Rizzo M.
    Oncol Rep; 2005 Mar; 13(3):531-7. PubMed ID: 15706429
    [Abstract] [Full Text] [Related]

  • 9. [Usefulness of BTA Stat test (Bard) in the diagnosis of bladder cancer. Preliminary results and comparison with cytology and cystoscopy].
    Gutiérrez Baños JL, Martín García B, Hernández Rodríguez R, Portillo Martín JA, Correas Gómez MA, del Valle Schaan JI, Roca Edreira A, Villanueva Peña A, Gutíerrez García R, De Diego Rodríguez E, Rado Velázquez MA.
    Arch Esp Urol; 1998 Oct; 51(8):778-82. PubMed ID: 9859583
    [Abstract] [Full Text] [Related]

  • 10. The dilemma of suspicious urine cytology in patients being followed for bladder cancer.
    Raitanen MP, Aine R, Kylmälä T, Kallio J, Liukkonen T, Tammela T, Finnbladder Group.
    Ann Chir Gynaecol; 2001 Oct; 90(4):256-9. PubMed ID: 11820413
    [Abstract] [Full Text] [Related]

  • 11. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.
    Halling KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell EL, Sebo TJ, Cheville JC, Clayton AC, Krajnik KL, Ebert TA, Nelson RE, Burkhardt HM, Ramakumar S, Stewart CS, Pankratz VS, Lieber MM, Blute ML, Zincke H, Seelig SA, Jenkins RB, O'Kane DJ.
    J Urol; 2002 May; 167(5):2001-6. PubMed ID: 11956427
    [Abstract] [Full Text] [Related]

  • 12. Noninvasive detection of bladder cancer with the BTA stat test.
    Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I.
    J Urol; 1999 Feb; 161(2):443-6. PubMed ID: 9915422
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
    Nisman B, Barak V, Shapiro A, Golijanin D, Peretz T, Pode D.
    Cancer; 2002 Jun 01; 94(11):2914-22. PubMed ID: 12115379
    [Abstract] [Full Text] [Related]

  • 14. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
    Sawczuk IS, Bagiella E, Sawczuk AT, Yun EJ.
    Cancer Detect Prev; 2000 Jun 01; 24(4):364-8. PubMed ID: 11059567
    [Abstract] [Full Text] [Related]

  • 15. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A.
    J Urol; 2002 Aug 01; 168(2):465-9. PubMed ID: 12131289
    [Abstract] [Full Text] [Related]

  • 16. [Clinical evaluation of the bladder tumor marker "Tu-MARK-BTA"].
    Yogi S, Ikeuchi T, Yoshikawa H, Hamashima T, Sasaki H, Morikawa F, Onodera Y, Matsumoto K, Kai Y.
    Hinyokika Kiyo; 1991 Apr 01; 37(4):335-9. PubMed ID: 1891992
    [Abstract] [Full Text] [Related]

  • 17. [ImmunoCyt--a new urine test in diagnosis of bladder cancer].
    Feil G, Bichler KH, Päulgen-Nelde HJ, Hennenlotter J, Zumbrägel A, Stenzl A.
    Urologe A; 2003 Apr 01; 42(4):531-7. PubMed ID: 12715125
    [Abstract] [Full Text] [Related]

  • 18. Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder.
    Ianari A, Sternberg CN, Rossetti A, Van Rijn A, Deidda A, Giannarelli D, Pansadoro V.
    Urology; 1997 May 01; 49(5):786-9. PubMed ID: 9145993
    [Abstract] [Full Text] [Related]

  • 19. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A, Kumar R, Gupta NP.
    Jpn J Clin Oncol; 2006 Mar 01; 36(3):172-5. PubMed ID: 16520358
    [Abstract] [Full Text] [Related]

  • 20. [Urinary tumor marker for urothelial cancer].
    Ohtani M, Iwasaki A, Shiraiwa H.
    Gan To Kagaku Ryoho; 2001 Nov 01; 28(12):1933-7. PubMed ID: 11729491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 175.